title: [Preoperative parameters, including percent of positive biopsy cores, in predicting pathological findings after radical prostatectomy].
abstract: OBJECTIVE
  We investigated whether preoperative parameters predict pathological stage at radical prostatectomy for patients with clinically localized prostatic cancer.
  
  
  METHODS
  We studied a total of 160 men with clinically localized prostatic cancer (less than or equal to clinical T2) who underwent radical rertropubic prostatectomy at Wakayama Medical University. Clinical Ts patients are not included in this study. Preoperative parameters include patient age, Body Mass Index, preoperative serum PSA value, biopsy Gleason score, clinical stage, the percent of positive biopsy cores (%PosBx) and the percent of positive biopsy cores on the dominant side (%DomPosBx). Univariate and multivariate analysis were performed to examine the prognostic significance of these preoperative parameters. Significant independent factors were combined to create a table to predict pathologically organ confined disease.
  
  
  RESULTS
  Univariate analysis showed preoperative serum PSA value (p< 0.001), biopsy Gleason score (p =0.001), clinical stage (p = 0.026), %PosBx (p= 0.002) and %DomPosBx (p=0.003) were significantly related to the pathological stage. On multivariate analysis, serum PSA value (p< 0.01), biopsy Gleason score (p<0.05) and %DomPosBx (p<0.05) were significant independent predictors of pathological stage.
  
  
  CONCLUSIONS
  We provide two model combinations using preoperative clinical factors, one is a combination of serum PSA and biopsy Gleason score and the other is a combination of serum PSA and %DomPosBx, which define a new preoperative model for predicting pathological organ confined prostatic cancer. These combinations are useful and provide important information for urologists to determine the appropriate treatment strategy for clinically localized prostatic cancer.
authors.affiliation: Department of Urology, Wakayama Medical University.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Inagaki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kohjimoto
authors.forename: Keizo
authors.initials: K
authors.lastname: Hagino
authors.forename: Tomomi
authors.initials: T
authors.lastname: Kuramoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Mori
authors.forename: Kazurou
authors.initials: K
authors.lastname: Kikkawa
authors.forename: Akinori
authors.initials: A
authors.lastname: Iba
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Uekado
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Shinka
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology*; D012044:Regression Analysis; D012669:Seminal Vesicles / Q000473:pathology
chemical_list: D017430:Prostate-Specific Antigen